Long-term treatment with arsenite activates HER1 and HER2 through upregulating EGF, TGFα, and HSP90 in a human uroepithelial cell line
- 64 Downloads
Numerous reports have established a robust dose-response association among arsenic levels in drinking water and incidences of bladder cancer (Aballay et al. 2012; Su et al. 2011). However, the exact molecular mechanisms are not clearly explained until now. Existing evidences have indicated that the human epidermal growth factor receptors (HERs) are linked to the pathogenesis of human cancers (Kriegmair et al. 2018; Sanguedolce et al. 2019; Steuer et al. 2018; Xue et al. 2018) and have a prominent function in the advancement as well as progression of epithelial cancer (Appert-Collin et al. 2015; Esparis-Ogando et al. 2016; Yu et al. 2018). Overexpression of HER1 and HER2 has been also reported in the patients with bladder cancer (Rotterud et al. 2005; Xue et al. 2018).
Nevertheless, there are not any specific studies that focus on the mechanisms of HER1 and HER2 activation during arsenic-induced urothelial hyperplasia. Increased proliferation and migration have long been regarded as an...
KeywordsArsenite Cell proliferation Urothelium Human Epidermal Growth Factor Receptor
This work was supported by the National Natural Science Foundation of China (NSFC) (81673207 and 81373023) and the Program for Liaoning Innovative Research Team in University (LNIRT) (201610159000037).
Compliance with ethical standards
Conflict of interests
The authors declare that they have no conflict of interest.
- De Pauw I, Lardon F, Van den Bossche J, Baysal H, Fransen E, Deschoolmeester V, et al. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines. Mol Oncol. 2018;12(6):830–54. https://doi.org/10.1002/1878-0261.12197.CrossRefPubMedPubMedCentralGoogle Scholar
- Kriegmair MC, Wirtz RM, Worst TS, Breyer J, Ritter M, Keck B, et al. Prognostic value of molecular breast cancer subtypes based on Her2, ESR1, PGR and Ki67 mRNA-expression in muscle invasive bladder cancer. Transl Oncol. 2018;11(2):467–76. https://doi.org/10.1016/j.tranon.2018.02.001.CrossRefPubMedPubMedCentralGoogle Scholar
- Liao JB, Lee HP, Fu HT, Lee HS. Assessment of EGFR and ERBB2 (HER2) in gastric and gastroesophageal carcinomas: EGFR amplification is associated with a worse prognosis in early stage and well to moderately differentiated carcinoma. Appl Immunohistochem Mol Morphol. 2018;26(6):374–82. https://doi.org/10.1097/PAI.0000000000000437.CrossRefPubMedGoogle Scholar
- Steuer CE, Griffith CC, Nannapaneni S, Patel MR, Liu Y, Magliocca KR, et al. A correlative analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 expression in oropharyngeal squamous cell carcinoma. Mol Cancer Ther. 2018;17(3):710–6. https://doi.org/10.1158/1535-7163.MCT-17-0504.CrossRefPubMedPubMedCentralGoogle Scholar